» Articles » PMID: 36699001

Gender Differences in the Prevalence of Parkinson's Disease

Overview
Publisher Wiley
Specialty Neurology
Date 2023 Jan 26
PMID 36699001
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Parkinson's disease (PD) affects males more than females. The reasons for the gender differences in PD prevalence remain unclear.

Objective: The objective of this systematic review and meta-analysis was to update the overall male/female prevalence ratios (OPR).

Methods: We updated previous work by searching MEDLINE, SCOPUS, and OVID for articles reporting PD prevalence for both genders between 2011 and 2021. We calculated OPRs and investigated heterogeneity in effect estimates.

Results: We included 19 new articles and 13 articles from a previously published meta-analysis. The OPR was 1.18, 95% CI, [1.03, 1.36]. The OPR was lowest in Asia and appeared to be decreasing over time. Study design, national wealth, and participant age did not explain OPR heterogeneity.

Conclusion: Gender differences in PD prevalence may not be as stark as previously thought. Studies are needed to understand the role of other determinants of gender differences in PD prevalence.

Citing Articles

Race and ethnicity matter! Moving Parkinson's risk research towards diversity and inclusiveness.

Siddiqi S, Ortiz Z, Simard S, Li J, Lawrence K, Redmond M NPJ Parkinsons Dis. 2025; 11(1):45.

PMID: 40050644 PMC: 11885646. DOI: 10.1038/s41531-025-00891-7.


Sex and gender differences in the molecular etiology of Parkinson's disease: considerations for study design and data analysis.

Schaffner S, Tosefsky K, Inskter A, Appel-Cresswell S, Schulze-Hentrich J Biol Sex Differ. 2025; 16(1):7.

PMID: 39901234 PMC: 11789417. DOI: 10.1186/s13293-025-00692-w.


Effect of obstructive sleep apnea risk on sialorrhea in patients with Parkinson's disease.

Ozkutlu O, Demir E, Unluer N, Sonkaya R Sleep Breath. 2025; 29(1):70.

PMID: 39776271 DOI: 10.1007/s11325-024-03234-7.


How well is the female population represented in clinical trials with infusion therapies for Parkinson's disease? A systematic review and metanalysis.

Smilowska K, Carvalho V, Szejko N, Costa J, Moro E, Antonini A Eur J Neurol. 2025; 32(1):e70024.

PMID: 39757738 PMC: 11702431. DOI: 10.1111/ene.70024.


Test, track, treat using wearable sensors for management of Parkinson's disease: 12‑month prospective observational United Arab Emirates study using Parkinson's Kinetograph (EmPark-PKG Study).

Metta V, Qamar M, Poplawska-Domaszewicz K, Ibrahim H, Hussain H, Nalarakettil A J Neural Transm (Vienna). 2024; 132(4):591-601.

PMID: 39730960 DOI: 10.1007/s00702-024-02873-0.


References
1.
Kis B, Schrag A, Ben-Shlomo Y, Klein C, Gasperi A, Spoegler F . Novel three-stage ascertainment method: prevalence of PD and parkinsonism in South Tyrol, Italy. Neurology. 2002; 58(12):1820-5. DOI: 10.1212/wnl.58.12.1820. View

2.
Barbosa M, Caramelli P, Maia D, Cunningham M, Guerra H, Lima-Costa M . Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambuí study). Mov Disord. 2006; 21(6):800-8. DOI: 10.1002/mds.20806. View

3.
Eusebi P, Franchini D, De Giorgi M, Abraha I, Montedori A, Casucci P . Incidence and prevalence of Parkinson's disease in the Italian region of Umbria: a population-based study using healthcare administrative databases. Neurol Sci. 2019; 40(8):1709-1712. DOI: 10.1007/s10072-019-03872-w. View

4.
Lim S, Tan A, Ahmad-Annuar A, Klein C, Tan L, Rosales R . Parkinson's disease in the Western Pacific Region. Lancet Neurol. 2019; 18(9):865-879. DOI: 10.1016/S1474-4422(19)30195-4. View

5.
El-Tallawy H, Farghaly W, Shehata G, Rageh T, Hakeem N, Hamed M . Prevalence of Parkinson's disease and other types of Parkinsonism in Al Kharga district, Egypt. Neuropsychiatr Dis Treat. 2014; 9:1821-6. PMC: 3843639. DOI: 10.2147/NDT.S48318. View